<DOC>
	<DOCNO>NCT02089503</DOCNO>
	<brief_summary>Main Objective : The main objective retrospective observational study describe evolution visual acuity measure ETDRS ( Early Treatment Diabetic Retinopathy Study ) scale , patient exudative Age-Related Macular Degeneration ( ARMD ) , treat Lucentis , real condition care , term mean change Best Corrected Visual Acuity ( BCVA ) , measure 24 month ( ± 4 week ) .</brief_summary>
	<brief_title>Monocentric Retrospective Observational Study Patients With Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients exudativesubfove ARMD , regardless neovessel type initial visual acuity ; 2 Patients treat department intra vitreous injection Lucentis ® study period ( 08/2011 02/2013 ) ; 3 If eye eligible , analyze ; 1 . Patients receive , study eye , treatment Vascular endothelial growth factor ( VEGF ) Lucentis ® three month precede start study . For received combination therapy , nature treatment specify take account subgroups statistical analyzes ; 2 . Patients high myopia neovessel related exudativeARMD ;</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>